Fig. 5: NO.0449-0145 suppresses NSCLC xenograft tumors.

a–c Tumor volumes and weights monitored from mice (n = 5 per group) treated with vehicle or different dose of NO.0449-0145 (3.125, 6.25, and 12.5 mg/kg) every 2 days. d Mice body weights monitored during treatment. e Representative micrographs of H&E staining and IHC staining for Ki67. f Representative micrographs of Immunofluorescence staining for γ-H2AX and 53BP1 foci. g, h Representative micrographs of IHC staining for BAK, BCL-XL, GSDMD, caspase-4, RIPK3, and phosph-RIPK3. The significance between treated samples and control samples was determined using a t-test. *p < 0.05; ***p < 0.001.